Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
about
Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationEverolimus for advanced pancreatic neuroendocrine tumors.Update on pancreatic neuroendocrine tumors.An Unusual Cause for Sister Mary Joseph's Nodule: A Case Report.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.A new era for the systemic therapy of neuroendocrine tumors.A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasEmerging therapies for the treatment of patients with advanced neuroendocrine tumors.Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumorCombination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.Pancreatic neuroendocrine tumors: a comprehensive review.Treatment options for unresectable neuroendocrine liver metastases.Sunitinib in pancreatic neuroendocrine tumors.Everolimus for the treatment of pancreatic neuroendocrine tumors.Streptozocin-based chemotherapy is not history in neuroendocrine tumours.Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.Systemic therapy for advanced pancreatic neuroendocrine tumorsSunitinib malate for the treatment of pancreas malignancies--where does it fit?Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potentialA randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.Pancreatic endocrine tumors: a report on a patient treated with sorafenib.Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study.Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy.Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
P2860
Q28551275-E9FBE5F3-0D04-4AAC-BDC8-A03A295EE3F7Q34399809-F50672AF-EBBF-47FB-B95A-6AB1872B4E00Q34453043-590D22F6-C9E8-4FF6-89BF-2535A6183D9AQ34900027-2AD0A574-C0EE-422A-A5CA-F54AC71F3805Q35081993-B803FCA5-C29A-4A21-A4EF-463A3F758AD4Q35584497-94A4F81E-5045-4263-8D61-A949CC9011A3Q35669138-8E50D64D-A705-4781-AA72-0122F09A2997Q35863865-3B591704-CAA4-4A2E-AF24-600BF10601E6Q36611857-C62D4D7F-7B01-40B7-81F8-82F24D4BFA6DQ36866607-F5F82685-02A6-4E77-B679-A02C0C3C7C28Q37166407-7A7DA9FB-8297-4E0C-9D54-0CF81D43E7C1Q37246135-0F2F479F-D1AE-41EF-9CCE-7DF14A26B018Q37981893-8785706F-663F-4727-BDBB-C3E4E585A57CQ37995947-E178DDF9-D8B6-41B6-BAD6-464B0DFB21E9Q38014498-AE6FBA87-DB86-4E21-9A1C-6D416147AABBQ38015764-2E1ACF69-8B64-4868-8E48-46C2A7BC076DQ38032923-09E3F843-10D5-44AD-B989-8DDC6A8B672AQ38035223-60324DA8-7C79-41CD-BE3D-D3F459B3BA50Q38066186-DB28C9F0-40AC-4F29-BBCA-063D36D81935Q38067034-B6A2A9E7-85DF-4D8E-BFE0-08BBB455D9B5Q38079854-960BF929-0ED8-4549-97B4-091A55936FAFQ38086310-250AB2EA-DE45-4A7F-853E-A1EE771AE190Q38099390-5D47C649-0927-4D85-9345-28734B94FCA8Q38458505-92D752DB-EF09-4AEE-A2C9-DDF644E7452AQ39952447-21FA6DE0-C5BA-47FE-A477-EF3A33E10D66Q41662598-30080099-375C-412D-A7D4-201CF975579BQ42776886-FC563C7B-FB24-4DA8-8BB4-9D995F3A4C58Q44210690-25BFB422-214B-4D1D-A22C-06C54728CB6CQ48377564-CD3F5534-1241-4B26-BB89-20BA17FAB265Q51143414-6C33FC7A-1DDD-40AE-85F3-CBB5D9B7D138Q51678616-16F155A5-6633-47A0-8212-ECCE1DE5E416Q53027231-91C88079-5389-46B0-B6B1-38B9A54023C1
P2860
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@ast
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@en
type
label
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@ast
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@en
prefLabel
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@ast
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@en
P2093
P1476
Lack of efficacy of streptozoc ...... d pancreatic endocrine tumors.
@en
P2093
A David McCollum
David P Ryan
Jeffrey W Clark
Lawrence N Shulman
Matthew H Kulke
Robert J Mayer
Sylvia Bartel
P304
P356
10.1097/01.COC.0000135343.06038.EB
P577
2004-10-01T00:00:00Z